Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07548372 · ClinicalTrials.gov registry record · NA
SPARK-CGM Implementation
A NA study, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 20,000
- Enrollment target
NCT07548372: Recruiting NA study, sponsored by Montefiore Medical Center.
NCT07548372 is a NA study that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 20,000 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1326% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07548372, a NA study, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 20,000 participants
- Enrollment target
Study Summary
Continuous glucose monitoring (CGM) is a technology that helps individuals with diabetes track their sugar levels in real-time, leading to more in-range blood sugars, fewer episodes of dangerously low blood sugar, and improved quality of life. Despite these benefits, CGM is not widely used in primary care settings, where most people receive their diabetes care. The investigators aim to make CGM more accessible and equitably prescribed in primary care practices. The study team will support primary care to increase CGM use with a program called SPARK-CGM (Supporting Primary Care Adoption, Resources, and Knowledge for CGM) across a large network of primary care clinics at Montefiore Medical Center. This program will provide primary care providers (PCPs) with education, tools, and support to incorporate CGM into their routine care for people with diabetes. Investigators plan to test SPARK-CGM to evaluate whether it increases CGM prescriptions who are eligible to receive this technology.
Primary Outcome
Time to first CGM prescription initiated by a primary care provider (PCP) will be defined as the date from a patient's first eligible primary care encounter during the study period to the date of the first CGM prescription, up to 18 months following intervention initiation, as recorded in the electronic health record. All CGM orders are captured in the EHR. Results will be summarized by study arm using descriptive statistics and analyzed using Cox proportional hazards models.
Interventions
- OTHER Standard of Care
- OTHER Enhanced CGM Interventions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2028-05 |
| Phase | NA |
What NCT07548372 shows while recruiting
NCT07548372 is an interventional study that assigns participants to a tested intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1326% higher).
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT07548372 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07548372 about?
NCT07548372 is a clinical study titled "SPARK-CGM Implementation". Continuous glucose monitoring (CGM) is a technology that helps individuals with diabetes track their sugar levels in real-time, leading to more in-range blood sugars, fewer episodes of dangerously low blood sugar, and improved quality of life. Despite these benefits, CGM is not widely used in primar...
What is the current status of trial NCT07548372?
This trial is currently recruiting. It is a NA study. The enrollment target is 20,000 participants. The study started on 2026-05-01. Estimated completion is 2028-05.
What interventions are being tested in trial NCT07548372?
The interventions under investigation include: Standard of Care (OTHER), Enhanced CGM Interventions (OTHER).
Who is sponsoring clinical trial NCT07548372?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07548372's enrollment target sits among peer trials
20,000 11th of 2000 higher than 1,990 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI